Pernix Therapeutics Hldgs buy klostergang
Zusammenfassung
Diese Einschätzung wurde am 07.12.15 mit einem Endkurs von 25,98 € beendet. Die Einschätzung zu Pernix Therapeutics Hldgs enttäuschte mit einer Rendite von -14,29 %. klostergang hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Pernix Therapeutics Hldgs | - | - | - | - |
iShares Core DAX® | -0,60 % | 0,65 % | 10,81 % | 15,40 % |
iShares Nasdaq 100 | -3,29 % | -4,19 % | 23,77 % | 40,77 % |
iShares Nikkei 225® | -0,80 % | -0,58 % | 8,39 % | 8,29 % |
iShares S&P 500 | -1,16 % | -0,86 % | 23,00 % | 41,15 % |
Kommentare von klostergang zu dieser Einschätzung
In der Diskussion Pernix Therapeutics Hldgs diskutieren
PTX is too cheap given its growth prospects and earnings trajectory!
Pernix Therapeutics (NASDAQ:PTX) is just one of a myriad small pharmaceuticals that have seen their stocks under pressure due to the fallout and collapse of Valeant Pharmaceuticals. After a big decline in its shares, the company reported blowout quarterly results this week.
At just $3.25 a share, the stock is too cheap given its growth prospects and earnings trajectory.
Earning Highlights: Pernix posted earnings of eight cents a share, seven cents a share above the consensus.Revenues climbed almost 55% year-over-year to just under $49 million for the quarter, just under $2 million above the consensus.Adjusted EBITDA increased to $8.7 million, compared to just under $7 million during the prior year period.
The company has three core products, Silenor, Treximit and Zohydro, that all have good growth prospects and decent patent expirations.